A clinical trial of a new targeted breast cancer drug, led by physicians at Massachusetts General Hospital (MGH) Cancer Center, has begun enrolling patients. The TEACH (Tykerb Evaluation After CHemotherapy) trial will investigate the experimental drug Tykerb (lapatinib) in patients with early-stage, HER2-positive breast cancer who have not been treated with Herceptin, another targeted drug used for the same type of tumor.
Patients suffering from the most common type of lung cancer experienced a 20-percent improvement in overall survival in a national clinical trial of a drug that chokes off the blood vessels nourishing tumors, a multicenter study has found.
The widely used breast cancer drug tamoxifen (Nolvadex?), which can become less effective over time, might retain its full strength indefinitely if used along with a second drug, according to new research in mice conducted by investigators from the National Cancer Institute (NCI), part of the National Institutes of Health, and their partners. The results appear in the December 11, 2006, issue of Cancer Cell.
Eli Lilly and Company (NYSE: LLY) announced today that it submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration’s Division of Drug Oncology Products (DDOP) for EVISTA? (raloxifene HCl) for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis and postmenopausal women at high risk for breast cancer.
SEER-Medicare analysis finds older men with early prostate cancer who were treated lived longer than those who were not treated. Study published in Dec. 13th issue of JAMA.
Recent findings of an observational study by researchers at the University of Pennsylvania School of Medicine suggest that men between 65-80 years of age who received treatment for early stage, localized prostate cancer lived significantly longer than men who did not receive treatment. The study will be published in the Dec. 13 issue of JAMA.
Majority of healthcare professionals surveyed agree that patients with prostate cancer should receive a licensed treatment wherever possible.
An anti-reflux valve developed to help esophageal cancer patients also has been shown to help those with bile duct obstruction, according to Kulwinder S. Dua, M.D., a research physician at the Medical College of Wisconsin in Milwaukee. The study, using the anti-reflux biliary stent in patients with cancer of the pancreas or bile duct, has been accepted for publication in the journal Gastrointestinal Endoscopy.
A monoclonal antibody developed by researchers at the University at Buffalo has been shown to extend significantly the survival of mice with human breast-cancer tumors and to inhibit the cancer’s spread to the lungs in the animals by more than 50 percent.
In a study to be published in the January 2007 issue of the FASEB Journal, scientists from Europe countries describe how the anti-cancer effects of olive oil may account for the significant difference in cancer rates among Northern and Southern Europeans. This conclusion is based on the outcomes of volunteers from Denmark, Finland, Germany, Italy and Spain, who consumed 25 milliliters (a little less than a quarter cup) of olive oil every day for three weeks.